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miR-125b controls apoptosis and temozolomide
resistance by targeting TNFAIP3 and NKIRAS2 in
glioblastomas
S Haemmig1, U Baumgartner1, A Glu¨ck1,3, S Zbinden1, MP Tschan1, A Kappeler1, L Mariani2, I Vajtai1 and E Vassella*,1
Diffusely infiltrating gliomas are among the most prognostically discouraging neoplasia in human. Temozolomide (TMZ) in
combination with radiotherapy is currently used for the treatment of glioblastoma (GBM) patients, but less than half of the
patients respond to therapy and chemoresistance develops rapidly. Epigenetic silencing of the O6-methylguanine-DNA
methyltransferase (MGMT) has been associated with longer survival in GBM patients treated with TMZ, but nuclear factor jB
(NF-jB)-mediated survival signaling and TP53 mutations contribute significantly to TMZ resistance. Enhanced NF-jB is in part
owing to downregulation of negative regulators of NF-jB activity, including Tumor necrosis factor alpha-induced protein
3 (TNFAIP3) and NF-jB inhibitor interacting RAS-like 2 (NKIRAS2). Here we provide a novel mechanism independent of TP53 and
MGMT by which oncogenic miR-125b confers TMZ resistance by targeting TNFAIP3 and NKIRAS2. GBM cells overexpressing
miR-125b showed increased NF-jB activity and upregulation of anti-apoptotic and cell cycle genes. This was significantly
associated with resistance of GBM cells to TNFa- and TNF-related inducing ligand-induced apoptosis as well as resistance to TMZ.
Conversely, overexpression of anti-miR-125b resulted in cell cycle arrest, increased apoptosis and increased sensitivity to TMZ,
indicating that endogenous miR-125b is sufficient to control these processes. GBM cells overexpressing TNFAIP3 and NKIRAS2
were refractory to miR-125b-induced apoptosis resistance as well as TMZ resistance, indicating that both genes are relevant targets
of miR-125b. In GBM tissues, high miR-125b expression was significantly correlated with nuclear NF-jB confirming that miR-125b is
implicated in NF-jB signaling. Most remarkably, miR-125b overexpression was clearly associated with shorter overall survival of
patients treated with TMZ, suggesting that this microRNA is an important predictor of response to therapy.
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Introduction
Gliomas, which account for at least 60% of primary brain
tumors in adults, are among the prognostically most discoura-
ging neoplasia in human. Depending on an individual
constellation of clinical variables and histological parameters,
median survival of patients ranges from some months to
12–15 years.1 Glioblastoma multiforme (GBM) represents the
highest grade (WHO grade IV) within the prevailing astrocytic
category of tumors, and present either as a de novo neoplasm
(primary GBM) or as the endpoint of tumor progression from a
lower grade precursor (secondary GBM). With optimal
treatment, the mean survival time of patients with GBM is
o15 months.
Surgical resection of GBM is essentially palliative as the
tumor infallibly recurs because of its pervasively infiltrative
growth.2 Patients receiving a combination of radio- and
chemotherapy using the alkylating agent temozolomide
(TMZ) tend to have a significantly longer overall and
progression-free survival, but not all patients benefit from
therapy and resistance develops rapidly in those patients.1,3
O6-methylguanine-DNA methyltransferase (MGMT) promoter
methylation2,4,5 and mutations in the isocitrate dehydrogen-
ase (IDH) subunits IDH1 and IDH26,7 correlate with a higher
rate of objective response to TMZ.
Constitutive activity of nuclear factor kB (NF-kB) signaling,
which occur in up to 90% of GBMs, is an important regulator of
proliferation, invasion and apoptosis.8,9 NF-kB is one of the
major factors modulating the ability of cancer cells to resist
apoptosis and to contribute to chemoresistance.10,11 NF-kB
comprises two subunits, commonly p50 (NFKB1)/p65 (RelA),
which in its inactive state is held in the cytoplasm by the
inhibitor of NF-kB (IkB). IkB is regulated by IkB kinase (IKK):
upon stimulation by external signals or stress, IKK is activated
and phosphorylates IkB and, thereby, targets IkB to ubiquitin-
mediated protein degradation. As a result, NF-kB is released
and translocates into the nucleus where it transactivates
multiple genes involved in proliferation, invasion and
apoptosis (reviewed by Nakanishi and Toi11).
Little information is available on the mechanism that may
account for constitutive activity of NF-kB in gliomas. Tumor
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necrosis factor alpha-induced protein 3 (TNFAIP3, also
known as A20), which acts in a negative feedback loop to
block NF-kB activity and is significantly associated with
resistance to TMZ, is frequently downregulated in GBM.12
TNFAIP3 catalyzes the cleavage of K63-linked ubiquitin
chains and the conjugation of K48-linked polyubiquitin chains,
thereby targeting receptor-interacting serine-threonine kinase
1 for degradation.13,14 Other negative regulators including NF-
kB inhibitor interacting RAS-like (NKIRAS) 1 and 2, which
interfere with proteosomal degradation of IkB, have also been
implicated in regulating NF-kB activity,15–18 but their role in
gliomas is poorly understood. In addition, the molecular
mechanism of downregulation of these negative regulatory
proteins in gliomas remains largely unknown.
In this study, we tested the hypothesis, whereby micro-
RNAs (miRNAs), short regulatory sequences that control
gene expression at the posttranscriptional level, would be
implicated in the regulation of NF-kB activity in gliomas.
miRNAs are incorporated into RNA-induced silencing
complex where they bind to target mRNAs and, depending
on the degree of complementarity to their target sequence,
confer mRNA degradation and/or translation inhibition of the
target gene (reviewed by Iorio and Croce19). miRNAs are
involved in the regulation of most basic cellular processes and
are also implicated in tumorigenesis where they act as
oncogenic or tumor suppressing miRNAs (reviewed by
Hwang and Mendel20).
Here we show that miR-125b, a brain-enriched miRNA, is
implicated in the regulation of NF-kB activity in GBM by
targeting TNFAIP3 and NKIRAS2. We show for the first time
that, owing to downregulation of these targets, miR-125b
controls proliferation and apoptosis, and confers TMZ
resistance of GBM cell lines in a MGMT- and TP53-
independent manner. These results can be extrapolated to
clinical cases of GBM, as miR-125b expression significantly
correlates with nuclear NF-kB in surgically obtained GBM
samples indicated that miR-125b is directly implicated in TMZ
resistance.
Results
miR-125a/b directly target TNFAIP3 and NKIRAS2 in
GBM cell lines. To identify miRNAs that are able to induce
NF-kB signaling, we searched target prediction databases
for putative target genes implicated in negative regulation of
NF-kB using miRNAs that are overexpressed in GBM
tissues.21 Target prediction algorithms using target scan
(www.targetscan.org), miRDB (http://mirdb.org) or DianaLab
(http://diana.cslab.ece.ntua.gr) revealed that TNFAIP3 and
NKIRAS2 are putative targets of oncogenic miR-125a and
miR-125b. miR-125a/b binding sites of eight nucleotides in
length were detected in the 30 UTR of each gene and in the
coding region of TNFAIP3 (Supplementary Figure S1A).
To assess direct regulation by miR-125a/b, luciferase
constructs containing predicted miR-125a/b binding sites from
the 30 UTR of the respective genes were cloned downstream of
the luciferase reporter gene (Supplementary Figure S1B).
U87 or LN-18 GBM cell lines, transiently transfected with
miR-125a/b precursors, displayed significantly lower luciferase
activity for reporter constructs containing the binding site for
TNFAIP3 or NKIRAS2 relative to the control construct
containing no binding site (Figures 1a and b). In contrast,
downregulation of luciferase activity was abrogated in
constructs in which the miR-125a/b binding site was mutated
(Figures 1a and b and Supplementary Figure S1B).
Consistent with these findings, the TNFAIP3 and NKIRAS2
mRNA levels were significantly reduced in U87 or LN-18 cells
that were transiently transfected with miR-125a/b precursors
(Figure 2a). In addition, the TNFAIP3 mRNA level was
inversely correlated with the level of miR-125b in 452 GBM
samples from the Cancer Genome Atlas (TCGA) database
(Supplementary Table S1). Under the same conditions,
TNFAIP3 and NKIRAS2 proteins were strongly reduced
(Figure 2b). These results clearly indicate that miR-125a/b
directly target TNFAIP3 and NKIRAS2.
Endogenous miR-125b is sufficient to regulate TNFAIP3
and NKIRAS2. Luciferase activity of the reporter construct
containing the target site of TNFAIP3 was almost maximally
reduced by endogenous miR-125a/b (Figure 1a, precursor
control). In contrast, transfection of GBM cells with
miR-125a/b precursor did not lead to a further reduction in
luciferase activity (Figure 1a). To confirm that endogenous
miR-125b is sufficient to downregulate TNFAIP3 and
NKIRAS2, GBM cell lines were transduced with a lentiviral
Figure 1 miR-125a and miR-125b directly target TNFAIP3 and NKIRAS2 in
GBM cells. Luciferase constructs containing the wild-type (TS) or mutated (mTS)
miR-125a/b target site from TNFAIP3 or NKIRAS2 were co-transfected with
pre-miR-125a/b or pre-control into GBM cells. Luciferase activity is presented for
TNFAIP3 (a) and NKIRAS2 (b) relative to the activity obtained with the construct Luc
containing no target site (n¼ 3)
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vector expressing antisense miR-125b giving rise to five-
times lower levels of miR-125b (Figure 2c). Indeed, anti-miR-
125b elicited a 2–2.5-fold increase in the mRNA level
(Figure 2c) and an increase, up to fivefold, in the protein
level (Figure 2d) of TNFAIP3 and NKIRAS2. In contrast, anti-
miR-125a was barely able to affect the mRNA or protein level
of TNFAIP3 or NKIRAS2 (data not shown) suggesting that
miR-125b is the relevant miRNA. In agreement with this
finding, the level of miR-125b was up to 20 times higher than
that of miR-125a in both GBM cell lines and GBM tissues
(Supplementary Figure S2). Hence, we focused on miR-125b
in subsequent experiments.
miR-125b is implicated in the regulation of NF-jB
activity. To assess whether miR-125b is able to induce
NF-kB activity, reporter assays were performed using a
construct containing the luciferase gene under the control of
a NF-kB-inducible promoter. miR-125b precursor elicited a
twofold higher luciferase activity in U87, LN-18 and U251
GBM cells compared with scrambled control (pre-control)
(Figure 3a and Supplementary Figure S3). Consistent with
these findings, blocking endogenous miR-125b by antisense
miR-125b resulted in reduced luciferase activity of U87 cells
(Figure 3a). Luciferase activity was barely detectable in
LN-18 cells overexpressing anti-miR-125b (data not shown).
However, results consistent with those for U87 cells were
obtained, when LN-18 cells were treated with TNFa, an
inducer of NF-kB activity (compare Figures 3a and b).
To confirm NF-kB activation using an independent
approach, nuclear and cytoplasmic fractions of cells cultured
in the presence or absence of TNFawere analyzed by western
blotting. The level of nuclear p65 was higher in cells
transfected with pre-miR-125b relative to cells transfected
with pre-control irrespective of whether they were cultured in
the presence of absence of TNFa (Figure 3c). Complementary
results were obtained for cytoplasmic fractions giving rise to
reduced p65 levels in cells overexpressing miR-125b
(Figure 3d). In addition, miR-125b conferred prolonged IkB
phosphorylation and concomitantly enhanced IkB degrada-
tion (Figure 3d) consistent with a concept that negative
feedback loops mediated by TNFAIP3 and NKIRAS2 are
abrogated in cells overexpressing miR-125b.
NF-kB is a transcriptional activator of anti-apoptotic and
proliferative genes.22 Transient transfection with miR-125b
precursor gave rise to increased levels of anti-apoptotic genes
Bcl-2 (Figure 4a) and c-IAP2 (Figure 4b) in 5/5 and 3/5 GBM
cell lines, respectively, whereas the levels of XIAP, survivin,
Bcl-xL and Bcl-w mRNAs were not affected (Supplementary
Figure S4). In agreement with this finding, miR-125b andBcl-2
were directly correlated at the RNA level in the cohort of TCGA
(Po0.0001, Supplementary Table S1). The cell cycle gene
CCND1 was induced in 4/5 cell lines upon transfection with
miR-125b precursor (Figure 4c).
Phenotypic analysis of miR-125b transfected cells.
Populations of U87 or LN-18 cells overexpressing
miR-125b precursor were 1.5–2-times higher in cell number,
whereas populations transduced with anti-miR-125b were
25% lower 3 days post transfection relative to scrambled
control (Figure 5a). To assess cell cycle progression, GBM
cells were transduced with anti-miR-125b and subsequently
treated with nocodazole to induce cell cycle arrest in G2/M.
Figure 2 TNFAIP3 and NKIRAS2 are regulated by miR-125a/b. (a) TNFAIP3 or NKIRAS2 mRNA levels by real-time PCR of cells transiently transfected with pre-miR-
125a/b relative to cells transfected with pre-control (n¼ 3). (b) Western blot of GBM cells transiently transfected with pre-miR-125b relative to pre-control. (c) mRNA levels
(n¼ 3) and (d) protein levels of TNFAIP3 and NKIRAS2 in cells lentivirally transduced with anti-miR-125b relative to cells transduced with anti-control
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In the case of U87 cells transduced with anti-control, 41% of
the population were in G1, whereas 75% of the cells
transduced with anti-miR-125b were in this phase of the cell
cycle (P¼ 0.0033), indicating that miR-125b promotes G1
progression. In contrast, anti-miR-125b had no effect on cell
cycle progression of LN-18 cells (Figure 5b).
To assess apoptosis, a caspase 3 cleavage assay was
performed. U87 or LN-18 cells overexpressing miR-125b
were significantly protected from TNFa or TNF-related
inducing ligand (TRAIL)-induced apoptosis (Figure 5c).
Conversely, experiments performed with cells transduced
with anti-miR-125b revealed an increased rate of TNFa-
induced apoptosis (Figure 5d).
miR-125b induces NF-jB activity by targeting TNFAIP3
and NKIRAS2. miR-125b protects GBM cells from
apoptosis, but is this owing to TNFAIP3 and/or NKIRAS2
repression? To address this question, miR-125b-refractory
retroviral expression constructs were made containing the
coding region of TNFAIP3 or NKIRAS2. Both constructs lack
miR-125a/b target sites in the 30 UTR, but the TNFAIP3
construct contains a predictive miR-125a/b target site in
the coding region which, however, did not affect protein
expression (Supplementary Figure S5A). U87 or LN-18 cells
transduced with TNFAIP3 or NKIRAS2 expression vectors
gave rise to high level expression of the respective gene
(Supplementary Figures S5B and C).
NF-kB activity was significantly reduced in cells over-
expressing TNFAIP3 and NKIRAS2, although this was more
Figure 3 miR-125b induces NF-kB activity. (a) NF-kB reporter activity of GBM
cells overexpressing miR-125b or anti-miR-125b relative to control cells (n¼ 6).
(b) NF-kB reporter activity of LN-18 cells overexpressing anti-miR-125b. Cells were
induced with 10 ng/ml TNFa for 4 h beginning 20 h post transfection (n¼ 6).
Expression of (c) nuclear p65 and (d) cytoplasmic p65, IkBa and phospho IkBa in
LN-18 cells transiently transfected with pre-miR-125b or pre-control by Western
blotting. Cells were induced with 10 ng/ml TNFa beginning at 48 h post transfection.
The ratio of pIkBa to IkBa protein levels is presented below the corresponding
Western blot
Figure 4 miR-125b induces the expression of NF-kB responsive genes. mRNA
levels of Bcl-2 (a), c-IAP2 (b) and CCND1 (c) by real-time PCR in GBM cell lines
overexpressing miR-125b relative to control transfected cells (n¼ 3)
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pronounced in U87 cells than in LN-18 cells (Figure 6a).
To assess if ectopic TNFAIP3 or NKIRAS2 can rescue the
phenotype obtained with miR-125b, NF-kB activity was
analyzed by luciferase reporter assays. miR-125b elicited a
1.8-fold induction of luciferase activity in U87 cells transduced
with control plasmid (pBABE), whereas only a 1.2–1.3-fold
induction of luciferase activity was obtained in cells ectopically
expressing NKIRAS2 or TNFAIP3 (Figure 6b). Comparable
results were also obtained in LN-18 cells giving rise to a
1.5-fold induction in pBABE cells and a 1.2–1.3-fold induction
in NKIRAS2 or TNFAIP3 cells, respectively.
In agreement with these results, miR-125b was less
efficient in cells ectopically expressing TNFAIP3 or NKIRAS2
than in pBABE control to induce nuclear accumulation of
NF-kB (Figure 6c, upper panel). In contrast, more NF-kB was
retained in the cytoplasm, whereas less phospho IkB was
expressed in cells ectopically expressing TNFAIP3 or
NKIRAS2 following transfection with miR-125b precursor
(Figure 6c, lower panel). In conclusion, these results indicate
that ectopic TNFAIP3 or NKIRAS2 can restore miR-125b-
induced activation of NF-kB.
Resistance to apoptosis by miR-125b depends on the
expression of TNFAIP3 and NKIRAS2. TNFa-induced
apoptosis was higher in cells ectopically expressing
TNFAIP3 or NKIRAS2 compared with pBABE control,
consistent with a reduced NF-kB activity (Figure 7a).
However, the ability of miR-125b to protect cells from
TNFa-induced apoptosis was significantly compromised in
cells ectopically expressing TNFAIP3 or NKIRAS2. This was
based on the finding that miR-125b elicited a 1.9 times lower
apoptosis rate in pBABE control, but only a 1.3–1.4 times
lower rate in cells expressing TNFAIP3 or NKIRAS2
compared with cells transfected with pre-control (Figure 7a).
miR-125b confers resistance to TMZ independent of
MGMT. Enhanced NF-kB activity is clearly associated with
resistance to TMZ.23 Consistent with this finding, U87 or
LN-18 cells transfected with miR-125b precursor were
significantly more resistant to TMZ than cells transfected
with pre-control (Figure 7b). Conversely, cells overexpres-
sing anti-miR-125b revealed a higher sensitivity towards
TMZ compared with the control (Figure 7c).
To assess if resistance to TMZ by miR-125b depends
on the expression of TNFAIP3 or NKIRAS2, retrovirally
transduced LN-18 cells were analyzed. Consistent with the
results obtained with untransduced cells, pBABE control
cells overexpressing miR-125b were significantly more
resistant to TMZ than control transfected cells (compare
Figures 7b and d). In contrast, miR-125b was significantly
compromised in its ability to confer resistance to TMZ in LN-18
cells ectopically expressing TNFAIP3. NKIRAS2 proved to be
Figure 5 miR-125b induces proliferation and apoptosis resistance in GBM cells.
(a) Population growth of U87 and LN-18 cells overexpressing miR-125b or anti-miR-
125b relative to the control using the resazurin assay (n¼ 3). (b) Cell cycle analysis
of nocodazole-treated cells by flow cytometry (n¼ 3). (c) Apoptosis. Cells were
transfected with pre-miR-125b or pre-control and treated with 10 ng/ml TNFa or
250 ng/ml TRAIL for 48 h beginning 24 h post transfection. Apoptosis was assessed
using the ApoTox-Glo Triplex assay (n¼ 3) (d) LN-18 cells overexpressing anti-
miR-125b or anti-control were induced with 10 ng/ml TNFa for 24 h and subjected to
the ApoTox-Glo Triplex assay (n¼ 3)
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less efficient than TNFAIP3 to restore miR-125b-induced
resistance to TMZ (Figure 7d).
NF-kB is a known transactivator of MGMT. To assess if
miR-125b confers TMZ resistance by inducing the expression
of MGMT, the steady-state level of MGMT mRNA was
analyzed in GBM cell lines overexpressing miR-125b. How-
ever, MGMT mRNA levels were unaffected in 4/5 cell lines
(Supplementary Figure S6), indicating that miR-125b induces
TMZ resistance independent of MGMT.
miR-125b levels correlate with nuclear NF-jB in the
cancer tissue and with the patient’s survival. Formalin-
fixed paraffin-embedded tumor tissues, obtained from a
collective of 60 GBM patients,24 were analyzed for the
expression of miR-125a/b (Supplementary Figure S2).
Kaplan–Meier survival curves revealed that miR-125b is an
unfavorable prognostic marker for patients treated with TMZ
in combination with radiotherapy (Figure 8a upper panel,
P¼ 0.02, log-rank Mantel–Cox). The median survival for
subgroups expressing high levels and low levels of miR-125b
was 9 and 18 months, respectively, and the hazard ratio was
0.26. In contrast, miR-125a was not a predictor of response
to TMZ (Figure 8a lower panel, P¼ 0.14). To validate our
collective, all tissues were also analyzed for the MGMT
promoter methylation status and IDH1/2 mutation status.
Both markers proved to be favorable prognostic markers in
this collective (Supplementary Figures S7A and B).
miR-125b expression was not correlated with MGMT
methylation or IDH mutation suggesting that miR-125b is an
independent prognostic marker (Supplementary Figure S8).
To assess if miR-125b affects NF-kB activity in tumor tissues,
tissue sections were analyzed by immunohistochemistry
using an antibody against p65 (Supplementary Figure S9).
Nuclear localization of NF-kB was correlated significantly with
miR-125b expression (Figures 8b, P¼ 0.03), indicating that
the results obtained in cell lines are also relevant for tumor
tissues. Again, no significant correlation was obtained
between miR-125a levels and nuclear NF-kB (Figure 8b).
Discussion
miR-125b is an ‘oncomiR’ which plays a central role in
molecular dysfunctions linking inflammation with cancer.25
It is implicated in proliferation, apoptosis and invasion and is
considered to be an important modulator of drug resistance in
different tumor systems.26 However, controversy exists whether
miR-125b is able to induce or inhibit these processes. Different
proapoptotic genes including TP53, Bmf, SIRT1, Bak1 and
Puma27–30 or anti-apoptotic genes including Bcl-2, Mcl-1,
Bcl-w31–33 were identified as targets of miR-125b. Importantly,
these studies often solely relied on data from miR-125b
overexpression and did not include rescue experiments
to show that the newly identified targets are relevant in
miR-125b-mediated cell death or proliferation responses.
In this study, we show that miR-125b induces proliferation
and anti-apoptosis by inducing NF-kB activity in GBM cell
lines. This is based on the findings that miR-125b induces:
(a) activity of a NF-kB reporter construct, (b) phosphorylation
and degradation of IkB and, as a consequence, nuclear
localization of NF-kB and (c) expression of known mediators
of NF-kB signaling including Bcl-2, c-IAP2 and CCND1.
The results obtained in vitro may be extrapolated to clinical
cases of GBM, as miR-125b expression significantly corre-
lates with nuclear NF-kB in surgically obtained GBM samples.
Figure 6 miR-125b induces NF-kB activity by targeting TNFAIP3 and NKIRAS2. (a) NF-kB activity of GBM cells retrovirally transduced with miR-125b-refractory
TNFAIP3, NKIRAS2 or pBABE control relative to untransduced cells (n¼ 6). (b) NF-kB activity of retrovirally transduced cells overexpressing miR-125b relative to pre-control
transfected cells (n¼ 6). (c) Western blot analysis of nuclear (upper panel) and cytoplasmic (lower panel) fractions of retrovirally transduced cells overexpressing miR-125b
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Furthermore, endogenous levels of miR-125b are sufficient to
regulate proliferation and resistance to apoptosis as indicated
by anti-miR-125b lentiviral transduction experiments (Figure 5).
In agreement with our results, miR-125b was among the top
hits in a functional genomics screen for miRNAs regulating
NF-kB activity in HEK293 cells,34 but this was not further
investigated. High level expression of miR-125b35 and
enhanced NF-kB activity8,9 are both confined to grade IV
(GBM) gliomas suggesting that miR-125b is less important in
low grade gliomas.
miR-125b directly targets negative regulators of NF-kB
activity including NKIRAS2 and TNFAIP3. Although both miR-
125a and miR-125b were shown recently to control the
expression of TNFAIP3 and NF-kB activity in DLBCL,36
endogenous levels of miR-125b, but not miR-125a, were
sufficient to affect the expression of TNFAIP3 in GBM cells.
Thus, the findings obtained in one cell system cannot be
extrapolated to another cell system. The finding that TNFAIP3
regulation by miR-125b is particularly important for GBM cells
is illustrated by the fact that luciferase activity of a construct
containing the miR-125a/b target site from TNFAIP3 was
almost maximally reduced by endogenous miR-125b
(Figure 1a). Further evidence for TNFAIP3 and NKIRAS2
being relevant targets of miR-125b in GBM cells is based on
our findings that NF-kB activity, anti-apoptosis and TMZ
resistance induced by miR-125b were abrogated in GBM cells
ectopically expressing miR-125b-refractory TNFAIP3 or
NKIRAS2. The rescue was not complete as TNFAIP3 and
NKIRAS2, both of which contribute to NF-kB activity, were not
ectopically expressed in the same cell. TNFAIP3 forms part of
a negative feedback loop to shut off NF-kB signaling.13,14
Both miR-125b37 and TNFAIP338 are induced by NF-kB
activity. In non neoplastic cells, one role of miR-125b may be
to modulate NF-kB activity by counteracting TNFAIP3
induction. In contrast, this negative feedback loop is abro-
gated in GBM cells owing to overexpression of miR-125b,
resulting in prolonged NF-kB signaling. Consistent with this
notion, miR-125b conferred prolonged IkB phosphorylation
and concomitantly enhanced IkB degradation (Figure 3d).
Reduced TNFAIP3 mRNA level in GBM is strongly
associated with TMZ resistance,12 but the underlying mole-
cular mechanism is largely unknown. We are the first to show
that this is at least in part owing to miR-125b. Thus we provide
a novel mechanism of TMZ resistance in GBM cells.
Consistent with this finding, miR-125b expression in the
tumor tissue is significantly correlated with the survival of
patients treated with TMZ. These findings are important as
TMZ is the major chemotherapeutic agent which is used for
the treatment of GBM, but o40% of GBM patients initially
respond to therapy and resistance develops rapidly.39
In addition, we show that NKIRAS2 is directly implicated in
apoptosis and contributes to chemosensitivity of GBM tumors
(see Figures 7a and d) and, thus, may constitute a new
Figure 7 miR-125b confers resistance to apoptosis and TMZ by targeting
TNFAIP3 and NKIRAS2. (a) Retrovirally transduced LN-18 cells were transfected
with pre-miR-125b or pre-control and induced with 10 ng/ml TNFa for 24 h (n¼ 3).
Apoptosis was assessed using the ApoTox-Glo Triplex assay. (b) Cell viability of
GBM cells overexpressing miR-125b in the presence of 200mM TMZ. Cell viability
was assessed 3 days after treatment with TMZ using resazurin assay (n¼ 3).
(c) Cell viability of GBM cells overexpressing anti-miR-125b or anti-control in the
presence of TMZ (n¼ 6). (d) Cell viability of LN-18 cells retrovirally transduced with
miR-125b-refractory TNFAIP3, NKIRAS2 or pBABE control following transfection
with pre-miR-125b or pre-control in the presence of TMZ (n¼ 6)
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chemoresistance marker. NKIRAS2 was reported to disturb
cytokine-induced NF-kB activation.15,16 Consistent with
previous findings,16 ectopic expression of NKIRAS2 resulted
in significantly less NF-kB activity (Figure 6a). Surprisingly,
miR-125b was reported to induce rather than reduce the
expression of NKIRAS2 in primary human macrophages,40
but the molecular mechanism was not further investigated.
We are the first to show that NKIRAS2 is not only a direct, but
also a relevant target of miR-125b in GBM cells.
miR-125b-induced TMZ resistance was independent of
TP53. This was indicated by the fact that although LN-18,
T98G, HS683 and U251 cells carry mutations or deletions in
the TP53 gene,41,42 miR-125b was capable of inducing Bcl-2
expression and protecting these cells from apoptosis to an
extent similar to that of TP53 proficient U87 cells
(Supplementary Figure S4). Likewise, miR-125b did not affect
the level of MGMT expression in most cell lines. Thus we
conclude that miR-125b induces resistance of GBM cells to
TMZ independent of MGMT or TP53. In addition, high level
expression of miR-125b was not inversely correlated with the
presence of IDH mutations or promoter methylation of the
MGMT gene in GBM tissues. Thus, miR-125b seems to be an
independent predictor of response to TMZ. Interestingly, U87
cells transduced with anti-miR-125b were considerably less
resistant to TMZ than anti-miR-125b transduced LN-18 cells,
which might be because of the fact that anti-miR-125b induces
cell cycle arrest in G1/G0 in the former.
In conclusion, our results indicate that miR-125b is an
important regulator of NF-kB activity by targeting TNFAIP3
and NKIRAS2 and, thereby, affects proliferation, apoptosis
and resistance to TMZ. The finding that miR-125b is a
predictor of response to TMZ in GBM patients underlies the
importance of miR-125b in NF-kB mediated processes. Our
results suggest that miR-125b represents an interesting target
for adjuvant therapy as blocking miR-125b by antagomiRs
would allow us to modulate the activity of NF-kB in GBM
tumors.
Materials and Methods
Cell lines and culture conditions. The human GBM cell line U87 MG,
LN-18, U251, HS683 and T98G were obtained from the American Type Culture
Collection (ATCC, Manassas, VA, USA). Cells were cultured in Iscove’s modified
Dublecco’s medium (Sigma-Aldrich, Buchs, Switzerland) supplemented with
2 mmol/l L-alanyl-L-glutamine, 1% penicillin/streptomycin and 5–10% fetal bovine
serum (Sigma-Aldrich) at 37 1C and 5% CO2.
Constructs. Luciferase constructs containing wild-type or mutated miR-125a/b
target sites from TNFAIP3 (BC114480) and NKIRAS2 (NM_001001349),
respectively, were obtained by cloning double-stranded oligonucleotides into an
XbaI site downstream of the luciferase gene of pcDNA3.0_luc.43 The coding
region of NKIRAS2 was amplified from genomic DNA using the primer pair
NKIRAS2_fw and NKIRAS2_rv and cloned between the BamHI and XhoI sites of
pBABE-puro (Addgene, Cambridge, MA, USA). A fragment encompassing the
50 end of TNFAIP3 was amplified from genomic DNA using the primer pair
TNFAIP3-50_fw and TNFAIP3-50_rv and released by cleavage with BglII and
HindIII. A fragment containing the 30 end of TNFAIP3 was released from pEGFR-
C1-A20 (Addgene) by cleavage with HindIII and XhoI. Both fragments were cloned
between the BamHI and XhoI sites of pBABE-puro to give rise to pBABE-
TNFAIP3. Primers used for cloning are indicated in Supplementary Table S2.
Transfection. Transfection was performed using Effectene, HiPerFect or
Attractene reagents (Qiagen, Hombrechtikon, Switzerland) essentially as
described43 except that 37.5 nM miRNA precursor hsa-miR-125a-5p and hsa-
miR-125b-5p, pre-miR negative control #1 (Ambion, Carisbad, CA, USA) was used
for transfection. Luciferase constructs and pGl4.32 reporter plasmid (Promega AG,
Du¨bendorf, Switzerland) were used at 1mg/ml and pRl-SV40 (Promega) was used
at 50 ng/ml transfection mix, respectively.
Figure 8 miR-125b expression is directly correlated with NF-kB activity in GBM
tissues and with the patient’s overall survival. (a) Comparison of the overall survival
of patients expressing4120% oro120% miR-125a/b in the tumor tissue relative
with the level of miR-125a/b in U87 cells using Kaplan–Meier survival plots.
The threshold was defined using a density blot, which gave rise to a bimodal
distribution with best separation at 120%. All patients were treated with TMZ.
Significance of correlation was assessed using log-rank (Mantel–Cox) test.
(b) Correlation of miR-125a/b expression and nuclear p65 in GBM tissues. A tumor
with 425% nuclear p65 was considered as constitutive active for NF-kB48
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Lentiviral and retroviral transduction. U87 and LN-18 cells were
transduced with a lentiviral expression vector for antisense hsa-miR-125b-1
(MZIP125b-PA-1) or scrambled control (System Bioscience, Mountain View, CA,
USA). Lentiviruses were produced as described.44 Cells were analyzed 3 days
post transduction. For ectopic expression of miR-125b-refractory TNFAIP3 and
NKIRAS2, U87 and LN-18 cells were transduced with pBABE-puro retrovirus
(Addgene) as described.45 Retrovirally transduced U87 and LN-18 cells were
selected with 0.8mg/ml and 1.5mg/ml puromycin, respectively.
Luciferase activity assays, cell cycle analysis, apoptosis assay
and cell viability assay. NF-kB reporter assays and luciferase activity
assays for target validation were carried out 30 and 48 h post transfection,
respectively, using a dual luciferase reporter assay (Promega) and an Infinite 200
reader (Tecan, Maennedorf, Switzerland).
Cell cycle analysis was performed essentially as described previously.46
Lentivirally transduced cells were treated with 80 ng/ml nocodazole for 16 h
beginning at 3 days post transduction. Flow cytometry was performed using a LSR
flow cytometer (Becton Dickinson, Allschwil, Switzerland) and FlowJo software
Version 9.5.3 (Tree Star, Ashland, OR, USA).
Apoptosis and viability were assessed using the ApoTox-Glo Triplex assay
(Promega). Apoptosis was induced by treating the cells with 10 ng/ml TNFa
(PeproTech, Rocky Hill, NJ, USA) or 250 ng/ml TRAIL (R&D Systems, Oxon, UK).
Cells were analyzed 24–48 h following stimulation.
TMZ (Sigma-Aldrich) sensitivity was assessed using the metabolic resazurin
assay (Sigma-Aldrich) in cells cultured in the presence of TMZ for 3 days.
RNA isolation and Real-time PCR. RNA extraction and real-time PCR
was performed as described in.43 Quantitative PCR of anti-apoptotic markers was
carried out using Quantitect primers (Qiagen); all other amplifications were done
using TaqMan assay (Applied Biosystems, Rotkreuz, Switzerland). Quantitative
PCR was performed using the one-step PCR system (Applied Biosystems). The
mean CT was determined from triplicate experiments. miRNA and mRNA levels
were normalized to the level obtained for RNU48 and GAPDH, respectively.
Changes in expression were calculated using the DDCT method.
Cell fractionation and western blot analysis. Cell fractionation was
performed using the nuclear extract kit according to the manufacturer’s instruction
(Active Motif, Carisbad, CA, USA). Protein concentrations were determined using
the Pierce BCA assay (Thermo Scientific, Reinach, Switzerland); 5 mg were loaded
per lane on a 4–20% Mini-PROTEAN TGX Gel (Bio-Rad Laboratories AG,
Reinach, Switzerland). Separated proteins were transferred to PVDF membranes
using the transfer turbo blot system (Bio-Rad). Monoclonal antibodies used in this
study were directed against TNFAIP3 (clone 59A426, diluted 1 : 100, Abcam,
Cambridge, UK), NKIRAS2 (clone ab57303, diluted 1 : 500, Abcam), IkBa (clone
E130, diluted 1 : 10 000, Abcam), phospho-IkBa (clone 5A5, diluted 1 : 2000, Cell
Signaling, Beverly, MA, USA), a-tubulin (clone B512, diluted 1 : 2000, Sigma-
Aldrich), histone 3 H3 (clone D1H2, diluted 1 : 2000, Cell Signaling) and p65
(polyclonal, diluted 1 : 2000, Abcam). Secondary goat anti-mouse-HRP and goat
anti-rabbit HRP antibodies (Bio-Rad) were used at 1 : 5000 or 1 : 7000,
respectively. Protein levels from total or cytoplasmic extracts were normalized to
a-tubulin and protein levels from nuclear extracts were normalized to histone 3.
Quantification of protein bands were performed using a luminescent image
analyzer LAS-4000 (Fujifilm, Dielsdorf, Switzerland) and Multi Gauge software
(Fujifilm Version 3.0).
Immunohistochemistry. For immunohistochemistry, 3-mm formalin-fixed
paraffin-embedded sections were treated with 25 mM citrate buffer, pH 6, in a
pressure cooker essentially as described.47 Anti-p65 (Abcam) was used at a 1 : 50
dilution. Mouse IgG1 (1 : 20, Dako, Glostrup, Denmark) was used as a negative
control. Sections were incubated with EnVisionþ system (labeled polymer
HRP anti-mouse, Dako) for 30 min at room temperature, visualized with
3,30-Diaminobenzidin (Sigma-Aldrich) for 8 min and counterstained with haematoxylin.
Laser capture microdissection, IDH1/2 mutation analysis and
MGMT promoter methylation analysis. Formalin-fixed paraffin-
embedded tissues from 58 surgical GBM samples were used for miRNA
expression, NF-kB, MGMT and IDH1/2 analysis. Clinical characteristics of the
patient’s collective are described elsewhere.24 Tumor tissue was collected by laser
capture microdissection as described.43 All experiments using human specimens
were done in compliance with the ethical guidelines of the Institute of Pathology,
University of Bern, and were reviewed by the institutional review board.
Statistics. Statistical analyzes were performed and Kaplan–Meier plots were
generated using the GraphPAD prism software (La Jolla, CA, USA). Statistical
differences were calculated using unpaired two-tailed Student’s t-test. A probability
of pr0.05 was considered statistically significant. Ns, not significant; *Po0.05;
**Po0.01; ***Po0.001; ****Po0.0001.
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